GSK'872 is primarily utilized in biochemical research to study the mechanisms of programmed cell death, specifically necroptosis. It functions as a potent and selective inhibitor of RIPK3 (Receptor-Interacting Protein Kinase 3), a key enzyme involved in the necroptosis pathway. Researchers employ GSK'872 to investigate the role of necroptosis in various diseases, including neurodegenerative disorders, inflammatory conditions, and certain types of cancer. By inhibiting RIPK3, this compound helps elucidate the cellular signaling pathways and molecular interactions that contribute to cell death, providing insights into potential therapeutic targets. Its application is crucial in developing strategies to modulate cell death pathways for the treatment of diseases where necroptosis plays a significant role.